Multicomponent vaccines

US6703025B1 · kind B1 · utility

Assignees

• INHIBITEX, INC. · US
• THE PROVOST, FELLOWS AND SCHOLARS OF THE COLLEGE OF THE HOLY AND UNDIVIDED TRINITY OF QUEEN ELIZABETH NEAR DUBLIN · IE
• THE TEXAS A&M UNIVERSITY SYSTEM · US

Inventors

• Joseph M. Patti · Weslaco, US
• Timothy J. Foster · Dublin, IE
• Magnus Hook · Houston, US

Key dates

• Filing date: Aug 31, 1999
• Grant date: Mar 9, 2004
• Expiry date: Aug 31, 2019

Classification

• Technology area (CPC A): Human Necessities
• CPC primary: A61P31/04
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

Multicomponent vaccines are provided which aid in the prevention and treatment of staphylococcal infections and which include certain selected combinations of bacterial binding proteins or fragments thereof, or antibodies to those proteins or fragments. By careful selection of the proteins, fragments, or antibodies, a vaccine is provided that imparts protection against a broad spectrum of Staphylococcus bacterial strains and against proteins that are expressed at different stages of the logarithmic growth curve. In one embodiment of the invention, a composition is provided that includes at least a collagen binding protein or peptide (or an appropriate site directed mutated sequence thereof) such as CNA, or a protein or fragment with sufficiently high homology thereto, in combination with a fibrinogen binding protein, preferably Clumping factor A (“ClfA”) or Clumping factor B (“ClfB”), or a useful fragment thereof or a protein or fragment with sufficiently high homology thereto. The vaccines and products of the present invention are advantageous in that they respond to the urgent need of the medical community for a substitute for small molecule antibiotics, w…